Brain Chemical Transporters: Solving the Ritalin Paradox

  • Published14 Nov 2012
  • Reviewed14 Nov 2012
  • Author Marilyn Fenichel
  • Source BrainFacts/SfN

A neuronal glutamate transporter clusters at post-synaptic sites. Confocal image of 11 day old cultured hippocampal neurons co-transfected with constructs expressing soluble cyan fluorescent protein (blue) and full-length glutamate transporter, EAAT3, fused to a yellow fluorescent protein (yellow). EAAT3 is seen in clusters on the dendritic surface and on spines and filopodia, whereas the soluble cyan fluorescent protein fills the entire cell.
Courtesy, with permission: C. Cheng, G. Glover, G. Banker, and S.G. Amara, 2002, The Journal of Neuroscience, 22:10643-52

For decades, researchers have been studying attention deficit hyperactivity disorder (ADHD), but identifying the scientific underpinnings of the disorder has been challenging. In recent years, painstaking research at the molecular and cellular level has yielded important new insights.

Brain chemical transporters, like the ones for glutamate shown in yellow, may be important in human health and disease, including ADHD.

What has been particularly puzzling is why stimulants such as methylphenidate (Ritalin®) have a calming effect on people with ADHD — the so-called Ritalin paradox. Interestingly, studying addictive drugs such as cocaine has helped answer this question. That’s because cocaine and methylphenidate are quite similar. Research has shown that cocaine and other stimulants block cells from disposing of dopamine, a brain chemical that produces pleasurable feelings. 

How does dopamine work? During pleasurable experiences, it is released into the synapse, the space between communicating brain cells. It then binds to receptors in the receiving cell that specifically recognize and respond to dopamine. In the sending cell, the dopamine transporter is responsible for the re-uptake and storage of the extra dopamine in the synapse. Cocaine blocks the transporters, causing dopamine to accumulate in the synapse. 

This finding opened the door to a new research path. Research by SfN Past President Susan Amara made studying dopamine transporters in depth possible. Amara and her colleagues figured out how to clone the gene for another transporter, for the brain chemical norepinephrine. This breakthrough allowed Amara and others to identify and study the genes for many other neurotransmitter transporters, including the dopamine transporter. Now, researchers could study how drugs interact with transporters, how the transporters function under different conditions, and how they are regulated. They could also create mice without any transporters at all.

Calming hyperactivity in mice

The role for dopamine transporters in the Ritalin paradox became clear once researchers in Marc Caron’s laboratory began studying their function in “knockout” mice — mice bred to lack dopamine transporters. Studies showed these mice were unable to clear dopamine. Behaviorally, the mice were hyperactive, much like children with ADHD. At this point, the relationship between dopamine and ADHD began to emerge. It was further clarified when the researchers gave the knockout mice cocaine or amphetamines. As with many children with ADHD who take Ritalin, the drugs calmed the rats down, suggesting that without dopamine transporters, stimulants behave quite differently. 

Further investigation, however, raised the concern that knockout mice were too far removed from children with ADHD, who did not lack dopamine transporters, to be a good research model. To address this issue, scientists made “knockdown” mice, mice that made fewer dopamine transporters. Although not as impaired as the knockouts, the knockdown mice were also hyperactive. And similarly, stimulant drugs calmed the knockdown mice. This study provided additional evidence of the connection between hyperactivity and the dopamine transporter. 

Research extends to humans

Research in people has validated these mouse studies. Using positron emission tomography (PET) scans, researchers compared brain activity of adults with and without ADHD. The study suggested that people with ADHD have lower levels of both dopamine receptors and transporters than other healthy adults. 

Recently, researchers in the laboratory of Randy Blakely, one of Amara’s early collaborators, identified a change in the gene sequence of the dopamine transporter associated with ADHD in people. Research showed this genetic change altered the distribution and function of dopamine transporters in cells. This research brings us one step closer to understanding the cellular and molecular underpinnings of ADHD. 

Viewed together, this body of work is beginning to make the case that ADHD is the result of impaired function of the dopamine system. Beginning with Amara’s initial basic science investigation of transporter function, researchers are getting closer to identifying how ADHD affects the brain and why a stimulant is an effective treatment. This research may one day identify medications that can better target this system, easing problems associated with ADHD.

CONTENT PROVIDED BY

BrainFacts/SfN

Research & Discoveries

See how discoveries in the lab have improved human health.

Read More

Neuroscience in the News

Check out the latest news from the field.

Read More

Find a Neuroscientist

Engage local scientists to educate your community about the brain.

Search